212 related articles for article (PubMed ID: 26627687)
21. Prevalence of Persistent Renal Dysfunction in Perinatally HIV-infected Thai Adolescents.
Bunupuradah T; Phupitakphol T; Sophonphan J; Prasitsuebsai W; Anugulruengkitt S; Jantarabenjakul W; Sopa B; Ruxrungtham K; Chanakul A; Puthanakit T;
Pediatr Infect Dis J; 2018 Jan; 37(1):66-70. PubMed ID: 28719505
[TBL] [Abstract][Full Text] [Related]
22. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
[TBL] [Abstract][Full Text] [Related]
23. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
24. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.
Hamzah L; Jose S; Booth JW; Hegazi A; Rayment M; Bailey A; Williams DI; Hendry BM; Hay P; Jones R; Levy JB; Chadwick DR; Johnson M; Sabin CA; Post FA
J Infect; 2017 May; 74(5):492-500. PubMed ID: 28130143
[TBL] [Abstract][Full Text] [Related]
25. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
[TBL] [Abstract][Full Text] [Related]
26. The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.
Salome T; Kasamba I; Mayanja BN; Kazooba P; Were J; Kaleebu P; Munderi P;
AIDS Res Ther; 2016; 13(1):28. PubMed ID: 27582777
[TBL] [Abstract][Full Text] [Related]
27. Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients.
Casado JL; Santiuste C; Vazquez M; Bañón S; Rosillo M; Gomez A; Perez-Elías MJ; Caballero C; Rey JM; Moreno S
AIDS; 2016 Jun; 30(9):1423-31. PubMed ID: 26919733
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.
Peyriere H; Cournil A; Casanova ML; Badiou S; Cristol JP; Reynes J
PLoS One; 2015; 10(11):e0142491. PubMed ID: 26571117
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir-Related Nephropathies in HIV-Infected Patients.
Lai S; Mariotti A; Lai C; Testorio M; Carta M; Innico G; Frassetti N; Mangiulli M; D'Angelo A; Russo GE
Curr Vasc Pharmacol; 2015; 13(5):670-5. PubMed ID: 25412689
[TBL] [Abstract][Full Text] [Related]
30. Renal dysfunction among adult HIV/AIDS patients on antiretroviral therapy at a tertiary facility in Ghana.
Obiri-Yeboah D; Awuku YA; Alofa W; Charwudzi A; Aniakwa-Bonsu E; Obboh E; Nsiah P
BMC Nephrol; 2018 Nov; 19(1):333. PubMed ID: 30463531
[TBL] [Abstract][Full Text] [Related]
31. Renal tubular dysfunction associated with tenofovir therapy.
Mitra S; Priscilla R; Rajeev K; Sauradeep S; Rajkumar S; Cherian AO
J Assoc Physicians India; 2014 Jul; 62(7):580-2. PubMed ID: 25672029
[TBL] [Abstract][Full Text] [Related]
32. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Cooper RD; Wiebe N; Smith N; Keiser P; Naicker S; Tonelli M
Clin Infect Dis; 2010 Sep; 51(5):496-505. PubMed ID: 20673002
[TBL] [Abstract][Full Text] [Related]
33. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
[TBL] [Abstract][Full Text] [Related]
34. Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).
Touzard Romo F; Smeaton LM; Campbell TB; Riviere C; Mngqibisa R; Nyirenda M; Supparatpinyo K; Kumarasamy N; Hakim JG; Flanigan TP
HIV Clin Trials; 2014; 15(6):246-60. PubMed ID: 25433664
[TBL] [Abstract][Full Text] [Related]
35. Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function.
Estébanez M; Bernardino JI; Serrano L; Pérez-Valero I; Zamora FX; Montes-Ramírez ML; González-García JJ; Arribas JR
Enferm Infecc Microbiol Clin; 2016 Jan; 34(1):29-32. PubMed ID: 25735716
[TBL] [Abstract][Full Text] [Related]
36. Acute Kidney Injury, Risk Factors, and Prognosis in Hospitalized HIV-Infected Adults in South Africa, Compared by Tenofovir Exposure.
Seedat F; Martinson N; Motlhaoleng K; Abraham P; Mancama D; Naicker S; Variava E
AIDS Res Hum Retroviruses; 2017 Jan; 33(1):33-40. PubMed ID: 27478997
[TBL] [Abstract][Full Text] [Related]
37. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Decloedt EH; Lesosky M; Maartens G; Joska JA
AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
[TBL] [Abstract][Full Text] [Related]
38. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
[TBL] [Abstract][Full Text] [Related]
40. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?
Calcagno A; Fiumanò M; Zugna D; Cusato J; Montrucchio C; Marinaro L; Trentini L; Ferrara M; D'Avolio A; Pizzi C; Di Perri G; Bonora S
Pharmacogenomics J; 2019 Feb; 19(1):65-71. PubMed ID: 30405212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
